You searched for "retinovascular"
Treatment of diabetic macular oedema
Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...High-stakes scenarios in retinal vein occlusion: A survey of medico-legal implications
Central retinal vein occlusion (CRVO) is the second most common retinal vascular disease after diabetic retinopathy, and its clinical complexity often intersects with medico-legal scrutiny [1]. Missteps in timely diagnosis, inadequate follow-up or poor documentation can lead to patient harm...
Developments in Ophthalmology: Ophthalmic Radiation Therapy Techniques and Applications
Radiation was discovered by Wilhelm Roentgen in 1895, and since then has been used to treat a variety of cancers. Its therapeutic properties have been widely used for ocular and periocular tumours and inflammatory disease, but the present era is...
Ophthalmology (third edition)
If you are an ophthalmologist who enjoys books with coloured pictures, you’re no lone wolf. The third edition of Lang’s Ophthalmology will definitely pique your primal ophthalmologist instincts. You will be drawn to its soft-bound yet sturdy looking exterior. Flicking...
Paediatric uveitis in India
This article was a retrospective review of paediatric patients presenting to a tertiary hospital in India. Records over a three year period were reviewed. The authors highlight that children account for about 2.2-13.8% of uveitis patients and are at greater...
Treat-and-extend regimen in treatment of patients with type 3 neovascularisation
Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...UKEGS (UK and Éire Glaucoma Society) Conference 2024
Pretty soon it’s going to be the 9th of October, and a quick Wikipedia search will tell you of how this day in history has seen the founding of the Kingdom of Valencia, the initial whispers of the Prague Astronomical...Retina Subspecialty Day highlights from the RCOphth 2026 Annual Congress
Implementation of biosimilars in NHS retinal services A NHS England (NHSE) perspective Luke Nicholson (Moorfields Eye Hospital) explained that the NHSE perspective overall is structured on best value medicine for the patient and system, accounting for a finite budget and...Broadening of treatment options for potentially blinding retinal conditions
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...
IAC vs. IVC chemotherapy for RB
This a single centre retrospective review of consecutive patients between 1997 and 2014, of all sporadic unilateral retinoblastoma (RB) group D cases, treated with combined intravenous chemotherapy (IVC) and focal treatments (1997- 2008), or intra-arterial chemotherapy (IAC) treatment (2008 to...
